조영제 시장 보고서 : 유형, 모달리티, 용도, 투여 경로, 최종사용자, 지역별(2026-2034년)

The global contrast media market size reached USD 5.1 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 6.9 Billion by 2034, exhibiting a growth rate (CAGR) of 3.41% during 2026-2034. North America exhibits a clear dominance in the market, attributed to the escalating demand for radiopharmaceuticals. Moreover, the increasing demand for diagnostic imaging procedures, owing to the growing prevalence of neurological, cancer, and cardiovascular diseases, is one of the key factors stimulating the market growth.

MARKET SIZE & FORECASTS:

• Contrast media market was valued at USD 5.1 Billion in 2025.
• The market is projected to reach USD 6.9 Billion by 2034, at a CAGR of 3.41% from 2026-2034.

DOMINANT SEGMENTS:

• Type: Iodinated contrast media exhibits a clear dominance in the market as it contains iodine atoms, which can be used for x-ray-based imaging modalities, such as computed tomography (CT).
• Modality: X-ray/computed tomography (CT) accounts for the majority of the total market share propelled by the inflating popularity of diagnostic imaging procedures.
• Application: Interventional cardiology currently holds the largest market share, owing to the escalating demand for techniques, such as coronary angiography and percutaneous coronary interventions (PCI), which widely rely on contrast media to visualize the heart's vascular structure and function.
• Route of Administration: Intravenous/intrarterial route exhibits a clear dominance in the contrast media market share, owing to their effectiveness in delivering contrast agents directly into the bloodstream, thereby ensuring rapid distribution throughout the targeted organs or body.
• Region: North America leads the market due to the presence of major pharmaceutical companies and regulatory support from bodies like the FDA.

KEY PLAYERS:

• The leading companies in the market include Bayer AG, Beijing Beilu Pharmaceuticals Company Limited, Bracco Group, FUJIFILM Sonosite, Inc., GE HealthCare, Guerbet, iMAX, JB Pharma, Jodas Expoim Pvt. Ltd., Lantheus, SANOCHEMIA Pharmazeutika GmbH, TAEJOON PHARM Co. Ltd., Trivitron Healthcare, etc.

KEY DRIVERS OF MARKET GROWTH:

• Increasing Diagnostic Imaging Procedures: The increase in diagnostic imaging, such as MRI, CT, and X-ray procedures, is driving the constant use of contrast agents to provide more distinct images and enhance diagnostic capabilities.
• Increasing Prevalence of Chronic Diseases: The growing occurrence of chronic ailments like cancer, cardiovascular disease, and neurological disorders is necessitating sustained use of contrast-enhanced imaging for effective diagnosis and monitoring of treatment.
• Technological Developments: Consecutive advancements in contrast media compositions, such as the creation of safer and more effective agents with fewer side effects, are improving clinical results and widening their scope of application.
• Increasing Healthcare Infrastructure: Repeated investments in healthcare facilities, especially in developing countries, are making more sophisticated diagnostic services accessible, thus increasing the demand for contrast media.
• Positive Reimbursement Policies: Governments and commercial payers are favorably supporting diagnostic imaging procedures via reimbursement programs, leading to continued use of contrast agents within regular clinical practice.

FUTURE OUTLOOK:

• Strong Growth Outlook: Contrast media business is witnessing steady growth with favorable global healthcare expenditure, growing diagnostic capabilities, and technological improvements in imaging technologies.
• Market Evolution: The business is ever-developing, with contrast agents becoming more and more incorporated into precision medicine and interventional care, opening the door to broader application across clinical specialties and geographies.

Contrast media market is experiencing dynamic evolution, and various trends are driving its current and future path. Regulatory organizations are making regulations stricter regarding the safety, efficacy, and environmental toxicity of contrast agents. Producers are embracing compliance by incorporating sustainable production methodologies and enhancing waste control mechanisms. Gadolinium retention in the environment issues are inviting more scrutiny, paving the way for biodegradable and reduced-dose formulations. Organizations are aligning their businesses with changing regulatory paradigms to maintain long-term market sustainability. As the healthcare sector is transitioning toward outpatient procedures, imaging centers and ambulatory service providers are emerging as principal end users of contrast media. Such imaging centers are placing emphasis on high-throughput imaging services based on fast-acting and economical contrast agents. Suppliers are also modifying their product lines to address the service requirements of outpatient clinics, focusing on convenience, storage space, and quick patient turnaround.

CONTRAST MEDIA INDUSTRY TRENDS:

Rising Use of Diagnostic Imaging Studies

The healthcare systems of the world are conducting more diagnostic imaging tests, such as computed tomography (CT) scans, X-rays, magnetic resonance imaging (MRI), and ultrasounds, as a routine part of clinical evaluation. Diagnostic centers and hospitals are increasingly using contrast-enhanced studies to obtain better visualization of internal organs, blood vessels, and disease processes. Physicians are making more use of contrast agents to enhance the sensitivity and specificity of imaging findings, thus enhancing diagnosis and treatment planning. This increased demand for imaging is based on the aging population, rise in chronic disease incidence, and greater emphasis on preventive medicine. With medical imaging increasingly becoming an important part of contemporary medicine, contrast medium consumption is growing correspondingly. Another crucial aspect is that advances in imaging technologies are also being incorporated into clinical practices by healthcare providers. As per World Health Organization (WHO), worldwide, life expectancy at birth hit 73.3 years in 2024, a rise of 8.4 years since 1995. The global population of individuals aged 60 and above is expected to reach 1.4 billion by 2030. This trend is further going to drive the need for efficient diagnostic imaging solutions for the geriatric population.

Increasing Incidence of Chronic and Lifestyle Diseases

The burden of chronic and lifestyle-related diseases, such as cancer, cardiovascular disorders, diabetes, and neurological complications is being managed by the healthcare sector of the world. Doctors are increasingly using contrast-enhanced imaging to diagnose, monitor, and treat such diseases more efficiently. In oncology, for example, contrast agents are assisting radiologists in defining tumor margins, metastatic extent, and treatment response more clearly. In cardiology, contrast media are assisting in the assessment of coronary artery diseases, cardiac perfusion, and structural disorders. Neurological illnesses like stroke and multiple sclerosis are also necessitating contrast imaging for their proper evaluation and monitoring. With these long-term illnesses becoming increasingly common due to factors like aging populations, sedentary lifestyles, and environmental issues, demand for cutting-edge diagnostic imaging is gaining traction. This increase in disease burden is encouraging healthcare providers to make investments in imaging capacities, thereby constantly facilitating the development of the contrast media market in various regions of the world and varying healthcare systems. In 2024, A research group from IOCB Prague, in partnership with the University of Tubingen in Germany and the Faculty of Science at Charles University, created a novel type of contrast agent suitable for use in both magnetic resonance imaging (MRI) and positron emission tomography (PET). This advancement addressed a significant challenge that had formerly obstructed the combination of these two imaging methods into one device.

Innovation in Contrast Agent Formulations

Pharma companies are proactively investing in research and development (R&D) to develop more sophisticated, safer, and targeted contrast media formulations. Researchers are creating low-osmolar and iso-osmolar iodine-based agents, macrocyclic gadolinium-based agents, and biodegradable microbubble agents with better safety profiles and fewer adverse effects. These innovations are reducing the risk of complications like contrast-induced nephropathy and nephrogenic systemic fibrosis, particularly in patients with impaired renal function. Researchers are also designing agents with greater imaging accuracy and quicker clearance from the body. The growth of targeted and molecular contrast agents for particular disease indicators is also enhancing diagnostic precision. These progressive developments are allowing better personalized and effective imaging, improving patient outcomes and clinical decision-making. IMARC Group predicts that the global precision diagnostics market is projected to attain USD 207.0 Billion by 2033.

CONTRAST MEDIA MARKET GROWTH DRIVERS:

Development of Healthcare Infrastructure in Emerging Markets

The emerging markets are witnessing fast-paced healthcare change through rising government expenditure, private investment, and global aid. Diagnostic centers and hospitals in these markets are increasing their capabilities by making investments in advanced imaging technology and adding contrast-enhanced procedures to everyday use. Governments are also introducing public health programs that include early disease detection, which is stimulating broader applications of diagnostic imaging. Improved access to affordable health insurance and expanding middle classes are also facilitating access to quality healthcare services, such as contrast-based diagnostics. With the growth of healthcare infrastructure, demand for contrast media is rising. Pharmaceutical firms are countering by entering the markets, establishing local alliances, and offering products aligned to local needs.

Artificial Intelligence (AI) and Imaging Technology integration

Medical imaging is undergoing digitalization, with artificial intelligence (AI) and machine learning (ML) technologies increasingly forming an integral part of diagnostic practice. Radiologists and imaging facilities are increasingly adopting AI to improve image interpretation, streamline repetitive tasks, and maximize contrast agent usage. AI algorithms are assisting with accurate quantification of contrast uptake, enabling clinicians to determine optimal contrast dosage according to patient-specific features. These devices are also enhancing early abnormal detection, minimizing human mistake, and optimizing overall imaging efficiency. Machine manufacturers are steadily incorporating AI functionality into CT, MRI, and ultrasound machines, allowing real-time feedback and automatic adjustment of image parameters. This technology convergence is enhancing diagnostic performance while minimizing contrast agent volume, supporting both cost-effectiveness and patient safety.

Growing Demand for Minimally Invasive and Image-Guided Interventions

Minimally invasive interventions are increasingly becoming the treatment method of choice in a vast majority of clinical situations because they have shorter recovery times, fewer complications, and fewer hospital stays. Interventional radiology, specifically, is picking up pace as doctors carry out image-guided procedures like angiography, embolization, biopsy, and stent placement. Such procedures depend significantly on contrast media to obtain real-time imaging of internal structure and to direct instruments with high accuracy. Hospitals and surgical centers are constantly increasing their capabilities in interventional radiology and endovascular therapies, raising the use of contrast agents in both diagnostic and therapeutic applications. This trend is driven by technological advances in imaging technologies and procedure-specific contrast preparations. As minimally invasive methods become routine practice in ever more medical specialties, the need for contrast-enhanced imaging is increasing.

CONTRAST MEDIA MARKET SEGMENTATION:

Breakup by Type:

• Iodinated Contrast Media
• Gadolinium-based Contrast Media
• Microbubble Contrast Media
• Barium-based Contrast Media

Among these, iodinated contrast media currently exhibits a clear dominance in the market

Iodinated contrast media refer to contrast agents that contain iodine atoms used for x-ray-based imaging modalities, such as computed tomography (CT). Moreover, they can also be used in angiography, venography, fluoroscopy, and even occasionally, plain radiography. Besides this, key players are launching iodinated contrast media agents, as they enhance the diagnostic capabilities of CT and other radiographic imaging techniques. For example, in July 2022, Fresenius Kabi introduced the generic iodinated contrast media agent to alleviate the shortage. In addition to this, in October 2022, GE Healthcare entered into a long-term agreement with Chile-based mining company Sociedad Quimica y Minera de Chile S.A. (SQM) to secure its supply of iodine, a key ingredient for contrast media products used in computed tomography (CT) procedures globally.

Breakup by Modality:

• X-ray/Computed Tomography (CT)
• Magnetic Resonance Imaging (MRI)
• Ultrasound

Currently, X-ray/computed tomography (CT) accounts for the majority of the total market share

The growth in this segmentation is propelled by the inflating popularity of diagnostic imaging procedures. Additionally, these imaging techniques are fundamental in medical diagnostics due to their ability to provide quick, detailed views of the body's internal structures, thereby making them crucial for the early diagnosis, detection, and management of diseases. Besides this, various technological advancements in X-ray and CT imaging technologies to expand their application in clinical practice are elevating the contrast media market prices. For instance, in September 2023, Smiths Detection developed its HI-SCAN 6040 CTiX, an advanced cabin baggage screening system based on computed tomography (CT) technology, for the market across India. Similarly, in November 2023, Annalise.ai introduced the Annalise Triage software platform for chest X-rays and non-contrast head CT.

Breakup by Application:

• Radiology
• Interventional Radiology
• Interventional Cardiology

Among these, interventional cardiology currently holds the largest market share

The escalating demand for techniques, such as coronary angiography and percutaneous coronary interventions (PCI), which widely rely on contrast media to visualize the heart's vascular structure and function, is stimulating the segment's growth. Furthermore, the increasing prevalence of cardiovascular diseases, coupled with advancements in cardiac imaging technologies, are increasing the number of these procedures. Apart from this, the launch of medical programs related to interventional cardiology will continue to bolster the market in the coming years. For example, in May 2024, the Society for Cardiovascular Angiography & Interventions (SCAI) started its SCAI scientific sessions in Long Beach, California, bringing together more than 1,800 researchers, clinicians, and innovators in the field of interventional cardiology and endovascular medicine.

Breakup by Route of Administration:

• Intravenous/Intrarterial
• Oral Route
• Rectal Route
• Others

Currently, intravenous/intrarterial route exhibits a clear dominance in the contrast media market share

The intravenous and intraarterial routes of administration find widespread applications, owing to their effectiveness in delivering contrast agents directly into the bloodstream, thereby ensuring rapid distribution throughout the targeted organs or body. This method is pivotal for enhancing the clarity of images in several diagnostic imaging procedures, including MRI, CT scans, and angiography. The intravenous route is particularly prevalent because it can be used for a wide range of imaging studies that require a systemic distribution of the contrast agent and is relatively easy to administer. For instance, in May 2023, Guerbet, one of the global leaders in medical imaging, announced that based on the scientific and clinical evidence, the ACR Committee on Drugs and Contrast Media classified elucirem as a Group II agent. 6 and indicated for use in adults and children aged two years and older. On the other hand, the intraarterial route offers a more targeted approach. It is used in procedures, including coronary angiograms, where the contrast media is injected directly into the arteries of the heart to obtain detailed images of the coronary circulation.

Breakup by End User:

• Hospital, Clinics and Ambulatory Surgery Centers
• Diagnostic Imaging Centers

According to the contrast media market research report, the availability of advanced imaging equipment across hospitals is acting as a significant growth-inducing factor. In addition to this, clinics, particularly those specializing in specific fields like cardiology or oncology, use contrast media for targeted diagnostic purposes. Moreover, ambulatory surgery centers extensively adopt imaging technologies that require contrast media, particularly for preoperative and postoperative assessments. Besides this, diagnostic imaging centers cater to both referrals from hospitals and smaller clinics.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America exhibits a clear dominance in the market

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The expanding healthcare infrastructures and a high rate of medical imaging procedures are driving the regional market. For example, in April 2024, the Northwest Imaging Forums (NWIF) and International Contrast Ultrasound Society (ICUS) announced an educational partnership to aid in training sonographers to perform contrast-enhanced ultrasound (CEUS) examinations and administer intravenous ultrasound contrast agents. Besides this, the presence of major pharmaceutical companies is also acting as another significant growth-inducing factor. For instance, in September 2023, Philips introduced the microvascular imaging super resolution contrast-enhanced ultrasound (CEUS), which was showcased at the International Bubble Conference in Chicago. Furthermore, regulatory support from bodies like the FDA also plays a crucial role in the swift approval and adoption of new contrast agents, which is expected to fuel the regional market in the coming years. For example, in August 2023, Fresenius Kabi, a German healthcare company with headquarters in Illinois, launched an FDA-approved generic substitute for Gadavist, the gadolinium-based contrast agent commonly used during MRI exams.

COMPETITIVE LANDSCAPE:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• Bayer AG
• Beijing Beilu Pharmaceuticals Company Limited
• Bracco Group
• FUJIFILM Sonosite, Inc.
• GE HealthCare
• Guerbet
• iMAX
• JB Pharma
• Jodas Expoim Pvt. Ltd.
• Lantheus
• SANOCHEMIA Pharmazeutika GmbH
• TAEJOON PHARM Co. Ltd.
• Trivitron Healthcare

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global contrast media market in 2025?

2. What is the expected growth rate of the global contrast media market during 2026-2034?

3. What has been the impact of COVID-19 on the global contrast media market?

4. What are the key factors driving the global contrast media market?

5. What is the breakup of the global contrast media market based on the type?

6. What is the breakup of the global contrast media market based on the modality?

7. What is the breakup of the global contrast media market based on the application?

8. What is the breakup of the global contrast media market based on the route of administration?

9. What are the key regions in the global contrast media market?

10. Who are the key players/companies in the global contrast media market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Contrast Media Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Iodinated Contrast Media
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Gadolinium-based Contrast Media
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Microbubble Contrast Media
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Barium-based Contrast Media
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Modality

• 7.1 X-ray/Computed Tomography (CT)
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Magnetic Resonance Imaging (MRI)
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Ultrasound
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Application

• 8.1 Radiology
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Interventional Radiology
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Interventional Cardiology
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Route of Administration

• 9.1 Intravenous/Intrarterial
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Oral Route
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Rectal Route
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Others
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast

10 Market Breakup by End User

• 10.1 Hospital, Clinics and Ambulatory Surgery Centers
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Diagnostic Imaging Centers
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast

11 Market Breakup by Region

• 11.1 North America
  • 11.1.1 United States
    • 11.1.1.1 Market Trends
    • 11.1.1.2 Market Forecast
  • 11.1.2 Canada
    • 11.1.2.1 Market Trends
    • 11.1.2.2 Market Forecast
• 11.2 Asia-Pacific
  • 11.2.1 China
    • 11.2.1.1 Market Trends
    • 11.2.1.2 Market Forecast
  • 11.2.2 Japan
    • 11.2.2.1 Market Trends
    • 11.2.2.2 Market Forecast
  • 11.2.3 India
    • 11.2.3.1 Market Trends
    • 11.2.3.2 Market Forecast
  • 11.2.4 South Korea
    • 11.2.4.1 Market Trends
    • 11.2.4.2 Market Forecast
  • 11.2.5 Australia
    • 11.2.5.1 Market Trends
    • 11.2.5.2 Market Forecast
  • 11.2.6 Indonesia
    • 11.2.6.1 Market Trends
    • 11.2.6.2 Market Forecast
  • 11.2.7 Others
    • 11.2.7.1 Market Trends
    • 11.2.7.2 Market Forecast
• 11.3 Europe
  • 11.3.1 Germany
    • 11.3.1.1 Market Trends
    • 11.3.1.2 Market Forecast
  • 11.3.2 France
    • 11.3.2.1 Market Trends
    • 11.3.2.2 Market Forecast
  • 11.3.3 United Kingdom
    • 11.3.3.1 Market Trends
    • 11.3.3.2 Market Forecast
  • 11.3.4 Italy
    • 11.3.4.1 Market Trends
    • 11.3.4.2 Market Forecast
  • 11.3.5 Spain
    • 11.3.5.1 Market Trends
    • 11.3.5.2 Market Forecast
  • 11.3.6 Russia
    • 11.3.6.1 Market Trends
    • 11.3.6.2 Market Forecast
  • 11.3.7 Others
    • 11.3.7.1 Market Trends
    • 11.3.7.2 Market Forecast
• 11.4 Latin America
  • 11.4.1 Brazil
    • 11.4.1.1 Market Trends
    • 11.4.1.2 Market Forecast
  • 11.4.2 Mexico
    • 11.4.2.1 Market Trends
    • 11.4.2.2 Market Forecast
  • 11.4.3 Others
    • 11.4.3.1 Market Trends
    • 11.4.3.2 Market Forecast
• 11.5 Middle East and Africa
  • 11.5.1 Market Trends
  • 11.5.2 Market Breakup by Country
  • 11.5.3 Market Forecast

12 SWOT Analysis

• 12.1 Overview
• 12.2 Strengths
• 12.3 Weaknesses
• 12.4 Opportunities
• 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

• 14.1 Overview
• 14.2 Bargaining Power of Buyers
• 14.3 Bargaining Power of Suppliers
• 14.4 Degree of Competition
• 14.5 Threat of New Entrants
• 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

• 16.1 Market Structure
• 16.2 Key Players
• 16.3 Profiles of Key Players
  • 16.3.1 Bayer AG
    • 16.3.1.1 Company Overview
    • 16.3.1.2 Product Portfolio
    • 16.3.1.3 Financials
    • 16.3.1.4 SWOT Analysis
  • 16.3.2 Beijing Beilu Pharmaceuticals Company Limited
    • 16.3.2.1 Company Overview
    • 16.3.2.2 Product Portfolio
    • 16.3.2.3 Financials
  • 16.3.3 Bracco Group
    • 16.3.3.1 Company Overview
    • 16.3.3.2 Product Portfolio
    • 16.3.3.3 SWOT Analysis
  • 16.3.4 FUJIFILM Sonosite, Inc.
    • 16.3.4.1 Company Overview
    • 16.3.4.2 Product Portfolio
    • 16.3.4.3 Financials
    • 16.3.4.4 SWOT Analysis
  • 16.3.5 GE HealthCare
    • 16.3.5.1 Company Overview
    • 16.3.5.2 Product Portfolio
    • 16.3.5.3 Financials
    • 16.3.5.4 SWOT Analysis
  • 16.3.6 Guerbet
    • 16.3.6.1 Company Overview
    • 16.3.6.2 Product Portfolio
    • 16.3.6.3 Financials
    • 16.3.6.4 SWOT Analysis
  • 16.3.7 iMAX
    • 16.3.7.1 Company Overview
    • 16.3.7.2 Product Portfolio
  • 16.3.8 JB Pharma
    • 16.3.8.1 Company Overview
    • 16.3.8.2 Product Portfolio
    • 16.3.8.3 Financials
  • 16.3.9 Jodas Expoim Pvt. Ltd.
    • 16.3.9.1 Company Overview
    • 16.3.9.2 Product Portfolio
  • 16.3.10 Lantheus
    • 16.3.10.1 Company Overview
    • 16.3.10.2 Product Portfolio
    • 16.3.10.3 Financials
  • 16.3.11 SANOCHEMIA Pharmazeutika GmbH
    • 16.3.11.1 Company Overview
    • 16.3.11.2 Product Portfolio
  • 16.3.12 TAEJOON PHARM Co. Ltd.
    • 16.3.12.1 Company Overview
    • 16.3.12.2 Product Portfolio
  • 16.3.13 Trivitron Healthcare
    • 16.3.13.1 Company Overview
    • 16.3.13.2 Product Portfolio